Suppr超能文献

关于吸入性糖皮质激素生长抑制风险的调查问卷。

Questionnaire about the risk of growth suppression of inhaled corticosteroids.

作者信息

Wolthers Ole D

机构信息

Asthma and Allergy Clinic, Children's Clinic Randers, Randers, Denmark.

出版信息

BMJ Paediatr Open. 2019 Aug 30;3(1):e000533. doi: 10.1136/bmjpo-2019-000533. eCollection 2019.

Abstract

BACKGROUND

Inhaled corticosteroids are associated with a risk of growth suppression in children. The aim of the present study was to assess what children with asthma, lay people and paediatricians feel about the risk of growth suppression by inhaled corticosteroids.

METHODS

A questionnaire was completed by seven populations consisting of 9-19 years old children and adolescents with asthma; 9-19 year olds with another chronic illness; healthy 9-19 year olds; parents to children with chronic conditions; parents to healthy schoolchildren; young adults; and paediatricians.

RESULTS

A total of 1216 individuals completed the questionnaire. A total of 867 individuals (74.6%) would not worry about a risk of 1-year growth suppression in the range of 0.5-2 cm (range: 233 (63.3%) in parents to patients in a secondary referral centre to 59 (86.8%) in the group of paediatricians ( 53.3, df 12, p<0.001; γ -223, error 0.042, p<0.001). A total of 745 individuals (64.3%) said that a loss in final height of 0.5-2 cm would not worry them (range: 34 (54.0%) in paediatricians to 119 (76.3%) in parents to healthy children ( 49.5, df 12, p<0.001; γ -0.073, error 0.039, p=0.06).

CONCLUSIONS

Most children with asthma, lay people and paediatricians do not worry about the risk of growth suppression of inhaled corticosteroids in the range up to 2 cm. Paediatricians worry less about the risk of 1-year growth suppression but more about final height suppression than children with asthma and other groups of children and adults. Paediatricians need to address the different concerns of some of their patients on this issue.

摘要

背景

吸入性糖皮质激素与儿童生长抑制风险相关。本研究的目的是评估哮喘患儿、外行人及儿科医生对吸入性糖皮质激素导致生长抑制风险的看法。

方法

由七类人群完成一份问卷,包括9至19岁的哮喘儿童和青少年;患有其他慢性病的9至19岁人群;健康的9至19岁人群;慢性病患儿的父母;健康学童的父母;年轻人;以及儿科医生。

结果

共有1216人完成了问卷。共有867人(74.6%)不会担心1年生长抑制在0.5至2厘米范围内的风险(范围:二级转诊中心患儿的父母中有233人(63.3%)至儿科医生组中有59人(86.8%)(χ² = 53.3,自由度12,p < 0.001;γ = -223,误差0.042,p < 0.001)。共有745人(64.3%)表示最终身高降低0.5至2厘米不会让他们担心(范围:儿科医生中有34人(54.0%)至健康儿童的父母中有119人(76.3%)(χ² = 49.5,自由度12,p < 0.001;γ = -0.073,误差0.039,p = 0.06)。

结论

大多数哮喘患儿、外行人及儿科医生不担心吸入性糖皮质激素在2厘米范围内导致生长抑制的风险。与哮喘患儿及其他儿童和成人组相比,儿科医生对1年生长抑制风险的担忧较少,但对最终身高抑制的担忧更多。儿科医生需要解决部分患者在这个问题上的不同担忧。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e423/6720896/6558230832dc/bmjpo-2019-000533f01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验